Panacea Biotec Limited

As of June 30, 2026, Panacea Biotec Limited carries a market capitalization of 34.66B, placing it among publicly traded companies globally. Its enterprise value stands at 34.66B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Panacea Biotec Limited has 61.25M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Panacea Biotec Limited trades at an EV/EBITDA multiple of 264.37 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 5.15 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 34.66B versus a market cap of 34.66B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 5.18M in revenue per employee across its workforce of 1,298.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Panacea Biotec Limited recorded an income tax benefit of -14.40M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -103.60M and -71.20M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Panacea Biotec Limited's stock has declined approximately 29.18% over the past 52 weeks. The 50-day moving average sits at 376.71, while the 200-day moving average is 401.08.

Over the twelve months ended June 30, 2026, Panacea Biotec Limited generated 6.73B in revenue and converted that into -71.20M in net income, yielding earnings per share of -1.44. EBITDA reached 131.10M, while operating income came in at -303.80M.

Over the twelve months ended June 30, 2026, Panacea Biotec Limited posted a gross margin of 54.66, reflecting its pricing power and cost economics. The operating margin of -4.52 and net profit margin of -1.06 provide insight into operational efficiency.

Panacea Biotec Limited's most recent stock split took place on February 3, 2003 with a 1:10 split ratio.